OHSS
MCID: OVR029
MIFTS: 65

Ovarian Hyperstimulation Syndrome (OHSS)

Categories: Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Hyperstimulation Syndrome

MalaCards integrated aliases for Ovarian Hyperstimulation Syndrome:

Name: Ovarian Hyperstimulation Syndrome 57 12 59 75 37 29 13 55 6 44 15 40 73
Ohss 57 59 75
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous 57
Secondary Meig's Syndrome 12

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
symptoms occur only during pregnancy (usual onset after 6 weeks gestation)
major fluid shifts may occur in severe cases


HPO:

32
ovarian hyperstimulation syndrome:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 608115
Disease Ontology 12 DOID:5425
MeSH 44 D016471
Orphanet 59 ORPHA64739
MESH via Orphanet 45 D016471
UMLS via Orphanet 74 C0085083
ICD10 via Orphanet 34 N98.1
MedGen 42 C0085083
KEGG 37 H01039
UMLS 73 C0085083

Summaries for Ovarian Hyperstimulation Syndrome

UniProtKB/Swiss-Prot : 75 Ovarian hyperstimulation syndrome: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis.

MalaCards based summary : Ovarian Hyperstimulation Syndrome, also known as ohss, is related to polycystic ovary syndrome and ectopic pregnancy, and has symptoms including vomiting, abdominal pain and nausea. An important gene associated with Ovarian Hyperstimulation Syndrome is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Integrin Pathway. The drugs Ganirelix and Metformin have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and pituitary, and related phenotypes are ascites and abdominal pain

Disease Ontology : 12 An ovarian disease that is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular to the third space and has symptom abdominal pain, has symptom nausea and has symptom vomiting. This disease is an iatrogenic complication of assisted reproduction technology.

Wikipedia : 76 Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take... more...

Description from OMIM: 608115

Related Diseases for Ovarian Hyperstimulation Syndrome

Diseases related to Ovarian Hyperstimulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 polycystic ovary syndrome 30.7 CYP19A1 FSHR GNRH1
2 ectopic pregnancy 30.7 CGA GNRH1 VEGFA
3 retinal artery occlusion 30.1 F5 VEGFA
4 anuria 30.1 ALB REN
5 endometriosis 29.9 CYP19A1 GNRH1 VEGFA
6 infertility 29.6 CYP19A1 FSHB FSHR GNRH1
7 myocardial infarction 29.5 ALB CDH5 F5 REN VEGFA
8 ovarian disease 28.9 AMH CGA CYP19A1 FSHR GNRH1 REN
9 capillary leak syndrome 11.3
10 thrombosis 10.7
11 hypothyroidism 10.4
12 thrombophilia 10.3
13 ovarian cyst 10.3
14 adenoma 10.3
15 thrombophilia due to thrombin defect 10.2
16 peritonitis 10.2
17 hypogonadotropic hypogonadism 23 without anosmia 10.2 FSHR GNRH1
18 severe nonproliferative diabetic retinopathy 10.2 ALB VEGFA
19 acroosteolysis 10.2 ALB VEGFA
20 background diabetic retinopathy 10.2 ALB VEGFA
21 angiokeratoma circumscriptum 10.2 KDR VEGFA
22 hydrocele 10.2 CGA VEGFA
23 hypertensive nephropathy 10.2 ALB VEGFA
24 pseudovaginal perineoscrotal hypospadias 10.2 CGA GNRH1
25 skin hemangioma 10.2 KDR VEGFA
26 radiation proctitis 10.2 KDR VEGFA
27 gastric lymphoma 10.2 ALB VEGFA
28 breast cancer 10.2
29 ventricular fibrillation, paroxysmal familial, 1 10.2
30 respiratory failure 10.2
31 pulmonary edema 10.2
32 pituitary adenoma 10.2
33 epithelioid hemangioendothelioma 10.2 KDR VEGFA
34 capillary hemangioma 10.2 KDR VEGFA
35 ischemic colitis 10.2 F5 VEGFA
36 nodular prostate 10.2 GNRH1 KDR
37 angiomatous meningioma 10.2 KDR VEGFA
38 leukostasis 10.2 KDR VEGFA
39 retinal vascular occlusion 10.2 F5 VEGFA
40 benign essential hypertension 10.1 ALB REN
41 kidney papillary necrosis 10.1 ALB REN
42 central retinal vein occlusion 10.1 F5 VEGFA
43 lymphangioma 10.1 KDR VEGFA
44 orthostatic proteinuria 10.1 ALB REN
45 precocious puberty, male-limited 10.1 CYP19A1 FSHR
46 oocyte maturation defect 1 10.1 CGA CYP19A1
47 hydrops, lactic acidosis, and sideroblastic anemia 10.1 ALB VEGFA
48 luteoma 10.1 CGA CYP19A1
49 estrogen excess 10.1 CYP19A1 FSHR
50 coats disease 10.1 KDR VEGFA

Graphical network of the top 20 diseases related to Ovarian Hyperstimulation Syndrome:



Diseases related to Ovarian Hyperstimulation Syndrome

Symptoms & Phenotypes for Ovarian Hyperstimulation Syndrome

Symptoms via clinical synopsis from OMIM:

57
Abdomen:
ascites
abdominal pain

Genitourinary Internal Genitalia Female:
enlarged multilocular ovaries
pathology shows multiple serous and hemorrhagic follicular cysts lined by luteinized cells ('hyperreactio luteinalis')
ovaries return to normal size after delivery

Abdomen Gastrointestinal:
nausea


Clinical features from OMIM:

608115

Symptoms:

12
  • vomiting
  • abdominal pain
  • nausea

Human phenotypes related to Ovarian Hyperstimulation Syndrome:

59 32 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 59 32 hallmark (90%) Very frequent (99-80%) HP:0001541
2 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
3 increased circulating gonadotropin level 59 32 hallmark (90%) Very frequent (99-80%) HP:0000837
4 enlarged polycystic ovaries 59 32 hallmark (90%) Very frequent (99-80%) HP:0008675
5 abdominal distention 59 32 hallmark (90%) Very frequent (99-80%) HP:0003270
6 increased serum testosterone level 59 32 hallmark (90%) Very frequent (99-80%) HP:0030088
7 hypovolemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011106
8 pleural effusion 59 32 frequent (33%) Frequent (79-30%) HP:0002202
9 nausea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002018
10 hirsutism 59 32 hallmark (90%) Very frequent (99-80%) HP:0001007
11 peripheral edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0012398
12 hemorrhagic ovarian cyst 59 32 frequent (33%) Frequent (79-30%) HP:0012886
13 pulmonary edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0100598
14 generalized edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0007430
15 capillary leak 59 32 hallmark (90%) Very frequent (99-80%) HP:0030005
16 nausea and vomiting 59 Very frequent (99-80%)
17 abnormality of the genitourinary system 32 HP:0000119
18 ovarian cyst 59 Frequent (79-30%)

UMLS symptoms related to Ovarian Hyperstimulation Syndrome:


abdominal pain, nausea

MGI Mouse Phenotypes related to Ovarian Hyperstimulation Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 ALB AMH CDH5 CGA CYP19A1 F5
2 endocrine/exocrine gland MP:0005379 10.11 ALB AMH CDH5 CGA CYP19A1 FSHB
3 growth/size/body region MP:0005378 10.09 CDH5 CGA CYP19A1 F5 FSHR GNRH1
4 cardiovascular system MP:0005385 10.02 CDH5 CYP19A1 F5 FSHR KDR REN
5 integument MP:0010771 9.91 CDH5 CYP19A1 F5 FSHR GNRH1 KDR
6 liver/biliary system MP:0005370 9.87 ALB CDH5 CYP19A1 F5 GNRH1 KDR
7 nervous system MP:0003631 9.76 CGA CYP19A1 F5 FSHR GNRH1 KDR
8 neoplasm MP:0002006 9.65 ALB AMH FSHR GNRH1 VEGFA
9 normal MP:0002873 9.5 ALB CDH5 CYP19A1 GNRH1 KDR REN
10 reproductive system MP:0005389 9.28 AMH CDH5 CGA CYP19A1 FSHB FSHR

Drugs & Therapeutics for Ovarian Hyperstimulation Syndrome

Drugs for Ovarian Hyperstimulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ganirelix Approved Phase 4,Phase 3,Phase 2,Not Applicable 123246-29-7, 124904-93-4 25081094
2
Metformin Approved Phase 4,Not Applicable 657-24-9 14219 4091
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-28-2 5757
4
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
5
Cetrorelix Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120287-85-6 16129715 25074887
6
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Not Applicable 28014-46-2
7 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 979-32-8
8
Leuprolide Approved, Investigational Phase 4,Phase 3 53714-56-0 657181 3911
9
Progesterone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 57-83-0 5994
10
Cabergoline Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 81409-90-7 54746
11
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Nafarelin Approved Phase 4 76932-56-4 25077649 16129618
14
Menotropins Approved Phase 4,Phase 3,Not Applicable 61489-71-2, 9002-68-0 5360545
15
leucovorin Approved Phase 4 58-05-9 6006 143
16
Enoxaparin Approved Phase 4 9005-49-6 772
17
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
18
Dalteparin Approved Phase 4 9005-49-6
19
Buserelin Approved, Investigational Phase 4 57982-77-1
20
Levonorgestrel Approved, Investigational Phase 4 17489-40-6, 797-63-7 13109
21
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
22
Norgestrel Approved Phase 4 6533-00-2 13109
23
Estrone Approved Phase 4 53-16-7 5870
24
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 77-92-9 311
25
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
27 Deslorelin Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 57773-65-6
28
Enclomiphene Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15690-57-0
29 Triptorelin Pamoate Phase 4,Phase 3,Phase 2,Not Applicable
30 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Luteolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Contraceptive Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hypoglycemic Agents Phase 4,Not Applicable
37 Prolactin Release-Inhibiting Factors Phase 4,Phase 2,Phase 3,Not Applicable
38 Citrate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Zuclomiphene Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Clomiphene Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Chorionic Gonadotropin Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
42 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Not Applicable
43 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Not Applicable
44 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Corifollitropin Alfa Application in PCOS Patients Unknown status NCT02215135 Phase 4 Corifollitropin alfa
2 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
3 Metformin in Step-down Regimen Versus Conventional Low Dose Step-up Protocol in Patients With PCOS Undergoing IVF Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
4 Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Unknown status NCT01347268 Phase 4
5 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
6 Type of Gonadotropin and Embryo Kinetics of Development Unknown status NCT02402192 Phase 4 Corifollitropin alfa
7 Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders Unknown status NCT01926210 Phase 4
8 Preventive Application of GnRH Antagonist on Early OHSS Recruiting NCT03188471 Phase 4 GnRH antagonist;aspirin
9 Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome? Terminated NCT01714648 Phase 4 Triptorelin 0.2 mg
10 Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS Completed NCT02670304 Phase 4 letrozole;Aspirin
11 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
12 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4 Leuprolide acetate
13 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
14 Short Versus Long Protocol for IVF and IVF+ICSI Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
15 Hormone Evaluation in Artificial Reproductive Technology Recruiting NCT03737253 Phase 4 Follitropin alpha;Menotropin
16 Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation Terminated NCT01606709 Phase 4 GnRH agonist;hCG
17 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4 Menotropin;Progesterone vaginal insert;Follitropin beta;Progesterone in oil;leuprolide acetate
18 The Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate
19 Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration Recruiting NCT02330770 Phase 4 GnRHa and HCG;GnRHa then HCG (single low-dose);GnRHa then HCG (multiple low-doses)
20 Endometrial Advancement After Rec or u-HCG Triggering Completed NCT00953628 Phase 4 10000 IU urinary HCG;250 mcg recombinant HCG
21 Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF) Terminated NCT02221154 Phase 4
22 Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study Completed NCT01783301 Phase 4 FSH
23 The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation Completed NCT01065376 Phase 4
24 Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer Recruiting NCT03309436 Phase 4 Clomiphene Citrate protocol
25 Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles Completed NCT01233206 Phase 4 Metformin;Placebo administration
26 COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation Completed NCT02288143 Phase 4 COOL-COS
27 Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
28 Efficacy and Safety of Medication Used to Stimulate Ovulation Recruiting NCT02715336 Phase 4 Ovulation induction with hCG and Lupron (GnRH agonist)
29 Low-dose Gonal-f® in Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
30 Effect of LMWH on Pregnancy Outcome in Women With Multiple Failures of IVF-ET Not yet recruiting NCT03701750 Phase 4 Low Molecular Weight Heparin (enoxaparin sodium)
31 Metformin in Assisted Reproduction-MET-AR-study Terminated NCT00159575 Phase 4 Metformin / Placebo treatment for 4 months
32 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
33 Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Completed NCT03118830 Phase 4 Triptorelin;cetrorelix;Recombinant Follicle Stimulating Hormone
34 Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? Withdrawn NCT00804960 Phase 4 Letrozole;Std IVF Protocol
35 Follicular Steroid Genesis in Controlled Ovarian Stimulation Completed NCT02738580 Phase 4 COS with GnRH antagonists and rFSH;COS with GnRH antagonists and HP-HMG
36 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) Completed NCT01969201 Phase 4 Urofollitrophin;Follitrophin alpha
37 IVF Versus Gonadotropin Therapy in Women With CC Resistant PCOS Withdrawn NCT02458963 Phase 4 Gonadotropin
38 IVF Versus LOD in Women With CC Resistant PCOS Withdrawn NCT02456792 Phase 4
39 Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS Recruiting NCT02436226 Phase 4 Clomiphene citrate and Human chorionic gonadotropin (HCG);Clomiphene citrate
40 Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist Completed NCT01607203 Phase 4 Decapeptyl Daily;pregnyl
41 MENOPUR® Versus FOLLISTIM® Completed NCT00802360 Phase 4 Menotropin;Progestrone vaginal insert;follitropin beta;Progesterone in oil;Ganirelix
42 Menopur Mixed Protocol Completed NCT01417195 Phase 4 Bravelle;Menopur
43 Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
44 Pituitary Down-regulation Before IVF for Women With Endometriosis Terminated NCT01757249 Phase 4 Combined Oral Contraceptive Pill (Microgynon 30)
45 Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI Recruiting NCT03057574 Phase 4 Follitropin Alfa
46 Luteal Phase FSH in the IVF Poor Responder Completed NCT00225433 Phase 4 follitropin beta;ganirelix acetate
47 The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis Completed NCT01581359 Phase 4 Triptorelin acetate
48 Cetrorelix and Ganirelix Flexible Protocol for (IVF) Recruiting NCT03477929 Phase 4 Ganirelix Acetate;Cetrorelix Acetate
49 Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Recruiting NCT03177538 Phase 4 Corifollitropin alfa and menotropin;Follitropin alfa and lutropin alfa
50 NATural Ovarian Stimulation Active, not recruiting NCT02892942 Phase 4 Gonal-F®;Cetrotide®;Cetrotide®

Search NIH Clinical Center for Ovarian Hyperstimulation Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: ovarian hyperstimulation syndrome

Genetic Tests for Ovarian Hyperstimulation Syndrome

Genetic tests related to Ovarian Hyperstimulation Syndrome:

# Genetic test Affiliating Genes
1 Ovarian Hyperstimulation Syndrome 29 FSHR

Anatomical Context for Ovarian Hyperstimulation Syndrome

MalaCards organs/tissues related to Ovarian Hyperstimulation Syndrome:

41
Ovary, Endothelial, Pituitary, Liver, Bone, Kidney, Brain

Publications for Ovarian Hyperstimulation Syndrome

Articles related to Ovarian Hyperstimulation Syndrome:

(show top 50) (show all 1119)
# Title Authors Year
1
Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome. ( 29334275 )
2018
2
Ovarian hyperstimulation syndrome leading to ventriculoperitoneal shunt malfunction: Case report. ( 29655999 )
2018
3
GnRHa trigger and luteal coasting: a new approach for the ovarian hyperstimulation syndrome high-risk patient? ( 29102428 )
2018
4
Ascites Index - a novel technique to evaluate ascites in ovarian hyperstimulation syndrome: a concept-proof study. ( 29781072 )
2018
5
Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach? ( 29386731 )
2018
6
Ureteral obstruction and ruptured kidney following ovarian hyperstimulation syndrome. ( 29391290 )
2018
7
Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management. ( 29892142 )
2018
8
Multiorgan failure associated with severe ovarian hyperstimulation syndrome due to inadequate protocol optimisation: a rare but avoidable complication. ( 29507026 )
2018
9
The Ovarian Hyperstimulation Syndrome. ( 29544639 )
2018
10
Clinical parameters of ovarian hyperstimulation syndrome (OHSS) following different hormonal triggers of oocyte maturation in IVF treatment. ( 29446481 )
2018
11
Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection. ( 29334199 )
2018
12
Effects of electroacupuncture on luteal regression and steroidogenesis in ovarian hyperstimulation syndrome model rat. ( 29482802 )
2018
13
The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model. ( 29880170 )
2018
14
A Retrospective Study of Letrozole Treatment Prior to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome Undergoing In Vitro Fertilization at Risk of Ovarian Hyperstimulation Syndrome. ( 29925074 )
2018
15
Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis. ( 29602141 )
2018
16
Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome. ( 29105961 )
2018
17
Randomized trial of combined cabergoline and coasting in preventing ovarian hyperstimulation syndrome during in vitro fertilization/intracytoplasmic sperm injection cycles. ( 29055130 )
2018
18
Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation. ( 29057693 )
2018
19
Ovarian hyperstimulation syndrome induced by hormone therapy for breast cancer treatment. ( 29061360 )
2018
20
Unilateral pleural effusion as the sole clinical presentation of severe ovarian hyperstimulation syndrome: a systematic review. ( 29063807 )
2018
21
Clinical outcomes of frozen embryo transfer cycles after freeze-all policy to prevent ovarian hyperstimulation syndrome. ( 30018904 )
2018
22
Persistent megalocystic ovaries after ovarian hyperstimulation syndrome in a postpartum patient with polycystic ovarian syndrome: a case report. ( 30201001 )
2018
23
Concentration of soluble urokinase plasminogen activator receptor (suPAR) in the pre-ovulatory follicular fluid is associated with development of ovarian hyperstimulation syndrome during ovarian stimulation. ( 30232642 )
2018
24
Undetectable Serum Levels of Anti-Müllerian Hormone in Women with Ovarian Hyperstimulation Syndrome During In Vitro Fertilization and Successful Pregnancy Outcome: Case Report. ( 30256029 )
2018
25
OC05: Ultrasound and hematological early-luteal-phase predictors of severe ovarian hyperstimulation syndrome in high-risk patients following triggering of final oocyte maturation with human chorionic gonadotropin. ( 30284362 )
2018
26
Spontaneous Ovarian Hyperstimulation Syndrome with FSH Receptor Gene Mutation: Two Rare Case Reports. ( 30410807 )
2018
27
Rare genetic variants potentially involved in ovarian hyperstimulation syndrome. ( 30483911 )
2018
28
Genome-wide screening differential long non-coding RNAs expression profiles discloses its roles involved in OHSS development. ( 29869218 )
2018
29
Prevention and management of ovarian hyperstimulation syndrome. ( 28262238 )
2017
30
Sliding scale HCG trigger yields equivalent pregnancy outcomes and reduces ovarian hyperstimulation syndrome: Analysis of 10,427 IVF-ICSI cycles. ( 28441461 )
2017
31
A proteomic analysis identifies candidate early biomarkers to predict ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients. ( 28534980 )
2017
32
GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome. ( 28706366 )
2017
33
Gonadotropin-Releasing Hormone-Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome? ( 28558117 )
2017
34
The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome. ( 28795043 )
2017
35
Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome ( 29120551 )
2017
36
Ovarian hyperstimulation syndrome following GnRH agonist trigger-think ectopic. ( 28600619 )
2017
37
No-268-The Diagnosis and Management of Ovarian Hyperstimulation Syndrome. ( 29080733 )
2017
38
Correction to: Irani etA al., Unilateral pleural effusion as the sole clinical presentation of severe ovarian hyperstimulation syndrome: a systematic review. ( 29140149 )
2017
39
A novel oocyte maturation trigger using 1500A IU of human chorionic gonadotropin plus 450A IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. ( 29086322 )
2017
40
Ovarian torsion and spontaneous ovarian hyperstimulation syndrome in a twin pregnancy: A case report. ( 28371633 )
2017
41
Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility to ovarian hyperstimulation syndrome. ( 28462400 )
2017
42
Zinc finger gene 217 (ZNF217) Promoted Ovarian Hyperstimulation Syndrome (OHSS) through Regulating E2 Synthesis and Inhibiting Thrombospondin-1 (TSP-1). ( 28607476 )
2017
43
Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study. ( 29132339 )
2017
44
Atypical case of preterm ovarian hyperstimulation syndrome. ( 28228430 )
2017
45
Large-Volume Paracentesis, up to 27 L, With Adjuvant Vaginal Cabergoline in the Case of Severe Ovarian Hyperstimulation Syndrome with Successful Pregnancy Outcome: A Case Report. ( 29142455 )
2017
46
What is the best predictor of severe ovarian hyperstimulation syndrome in IVF? A cohort study. ( 28710674 )
2017
47
Elective frozen-thawed embryo transfer (FET) in women at risk for ovarian hyperstimulation syndrome. ( 29279182 )
2017
48
Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome. ( 27771155 )
2017
49
A New Perspective on the Risk of Hypercoagulopathy in Ovarian Hyperstimulation Syndrome Using Thromboelastography. ( 28299993 )
2017
50
Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. ( 28535578 )
2017

Variations for Ovarian Hyperstimulation Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Hyperstimulation Syndrome:

75
# Symbol AA change Variation ID SNP ID
1 FSHR p.Thr449Ile VAR_017244 rs28928870
2 FSHR p.Asp567Asn VAR_017245 rs28928871
3 FSHR p.Ser128Tyr VAR_039279
4 FSHR p.Thr449Ala VAR_039282
5 FSHR p.Ile545Thr VAR_039284
6 FSHR p.Met512Ile VAR_074535
7 FSHR p.Val514Ala VAR_074536
8 FSHR p.Ala575Val VAR_074537

ClinVar genetic disease variations for Ovarian Hyperstimulation Syndrome:

6 (show top 50) (show all 62)
# Gene Variation Type Significance SNP ID Assembly Location
1 FSHR NM_000145.3(FSHR): c.919G> A (p.Ala307Thr) single nucleotide variant Benign rs6165 GRCh37 Chromosome 2, 49191041: 49191041
2 FSHR NM_000145.3(FSHR): c.919G> A (p.Ala307Thr) single nucleotide variant Benign rs6165 GRCh38 Chromosome 2, 48963902: 48963902
3 FSHR NM_000145.3(FSHR): c.2039G> A (p.Ser680Asn) single nucleotide variant Benign rs6166 GRCh37 Chromosome 2, 49189921: 49189921
4 FSHR NM_000145.3(FSHR): c.2039G> A (p.Ser680Asn) single nucleotide variant Benign rs6166 GRCh38 Chromosome 2, 48962782: 48962782
5 FSHR NM_000145.3(FSHR): c.1346C> T (p.Thr449Ile) single nucleotide variant Pathogenic rs28928870 GRCh37 Chromosome 2, 49190614: 49190614
6 FSHR NM_000145.3(FSHR): c.1346C> T (p.Thr449Ile) single nucleotide variant Pathogenic rs28928870 GRCh38 Chromosome 2, 48963475: 48963475
7 FSHR NM_000145.3(FSHR): c.1699G> A (p.Asp567Asn) single nucleotide variant Pathogenic rs28928871 GRCh37 Chromosome 2, 49190261: 49190261
8 FSHR NM_000145.3(FSHR): c.1699G> A (p.Asp567Asn) single nucleotide variant Pathogenic rs28928871 GRCh38 Chromosome 2, 48963122: 48963122
9 FSHR NM_000145.3(FSHR): c.1345A> G (p.Thr449Ala) single nucleotide variant Pathogenic rs121909663 GRCh37 Chromosome 2, 49190615: 49190615
10 FSHR NM_000145.3(FSHR): c.1345A> G (p.Thr449Ala) single nucleotide variant Pathogenic rs121909663 GRCh38 Chromosome 2, 48963476: 48963476
11 FSHR NM_000145.3(FSHR): c.1634T> C (p.Ile545Thr) single nucleotide variant Pathogenic rs121909664 GRCh37 Chromosome 2, 49190326: 49190326
12 FSHR NM_000145.3(FSHR): c.1634T> C (p.Ile545Thr) single nucleotide variant Pathogenic rs121909664 GRCh38 Chromosome 2, 48963187: 48963187
13 FSHR NM_000145.3(FSHR): c.383C> A (p.Ser128Tyr) single nucleotide variant Pathogenic rs121909665 GRCh37 Chromosome 2, 49217768: 49217768
14 FSHR NM_000145.3(FSHR): c.383C> A (p.Ser128Tyr) single nucleotide variant Pathogenic rs121909665 GRCh38 Chromosome 2, 48990629: 48990629
15 FSHR NM_000145.3(FSHR): c.-29G> A single nucleotide variant Benign rs1394205 GRCh37 Chromosome 2, 49381585: 49381585
16 FSHR NM_000145.3(FSHR): c.-29G> A single nucleotide variant Benign rs1394205 GRCh38 Chromosome 2, 49154446: 49154446
17 FSHR NM_000145.3(FSHR): c.24G> T (p.Leu8Phe) single nucleotide variant Likely benign rs115030945 GRCh38 Chromosome 2, 49154394: 49154394
18 FSHR NM_000145.3(FSHR): c.24G> T (p.Leu8Phe) single nucleotide variant Likely benign rs115030945 GRCh37 Chromosome 2, 49381533: 49381533
19 FSHR NM_000145.3(FSHR): c.*256C> T single nucleotide variant Likely benign rs72873077 GRCh37 Chromosome 2, 49189616: 49189616
20 FSHR NM_000145.3(FSHR): c.*256C> T single nucleotide variant Likely benign rs72873077 GRCh38 Chromosome 2, 48962477: 48962477
21 FSHR NM_000145.3(FSHR): c.1576T> C (p.Leu526=) single nucleotide variant Uncertain significance rs138281715 GRCh37 Chromosome 2, 49190384: 49190384
22 FSHR NM_000145.3(FSHR): c.1576T> C (p.Leu526=) single nucleotide variant Uncertain significance rs138281715 GRCh38 Chromosome 2, 48963245: 48963245
23 FSHR NM_000145.3(FSHR): c.446+10T> C single nucleotide variant Likely benign rs200504733 GRCh38 Chromosome 2, 48990556: 48990556
24 FSHR NM_000145.3(FSHR): c.446+10T> C single nucleotide variant Likely benign rs200504733 GRCh37 Chromosome 2, 49217695: 49217695
25 FSHR NM_000145.3(FSHR): c.373C> A (p.Leu125Met) single nucleotide variant Uncertain significance rs886056151 GRCh38 Chromosome 2, 49017490: 49017490
26 FSHR NM_000145.3(FSHR): c.373C> A (p.Leu125Met) single nucleotide variant Uncertain significance rs886056151 GRCh37 Chromosome 2, 49244629: 49244629
27 FSHR NM_000145.3(FSHR): c.*563T> C single nucleotide variant Likely benign rs80295823 GRCh37 Chromosome 2, 49189309: 49189309
28 FSHR NM_000145.3(FSHR): c.*563T> C single nucleotide variant Likely benign rs80295823 GRCh38 Chromosome 2, 48962170: 48962170
29 FSHR NM_000145.3(FSHR): c.*199A> G single nucleotide variant Uncertain significance rs886056148 GRCh37 Chromosome 2, 49189673: 49189673
30 FSHR NM_000145.3(FSHR): c.*199A> G single nucleotide variant Uncertain significance rs886056148 GRCh38 Chromosome 2, 48962534: 48962534
31 FSHR NM_000145.3(FSHR): c.1831C> G (p.Leu611Val) single nucleotide variant Uncertain significance rs886056149 GRCh37 Chromosome 2, 49190129: 49190129
32 FSHR NM_000145.3(FSHR): c.1831C> G (p.Leu611Val) single nucleotide variant Uncertain significance rs886056149 GRCh38 Chromosome 2, 48962990: 48962990
33 FSHR NM_000145.3(FSHR): c.688A> G (p.Ile230Val) single nucleotide variant Uncertain significance rs367711694 GRCh38 Chromosome 2, 48968864: 48968864
34 FSHR NM_000145.3(FSHR): c.688A> G (p.Ile230Val) single nucleotide variant Uncertain significance rs367711694 GRCh37 Chromosome 2, 49196003: 49196003
35 FSHR NM_000145.3(FSHR): c.219G> A (p.Glu73=) single nucleotide variant Uncertain significance rs377397067 GRCh38 Chromosome 2, 49068224: 49068224
36 FSHR NM_000145.3(FSHR): c.219G> A (p.Glu73=) single nucleotide variant Uncertain significance rs377397067 GRCh37 Chromosome 2, 49295363: 49295363
37 FSHR NM_000145.3(FSHR): c.-58T> C single nucleotide variant Uncertain significance rs886056153 GRCh38 Chromosome 2, 49154475: 49154475
38 FSHR NM_000145.3(FSHR): c.-58T> C single nucleotide variant Uncertain significance rs886056153 GRCh37 Chromosome 2, 49381614: 49381614
39 FSHR NM_000145.3(FSHR): c.*111T> C single nucleotide variant Likely benign rs140106399 GRCh37 Chromosome 2, 49189761: 49189761
40 FSHR NM_000145.3(FSHR): c.*111T> C single nucleotide variant Likely benign rs140106399 GRCh38 Chromosome 2, 48962622: 48962622
41 FSHR NM_000145.3(FSHR): c.1596G> A (p.Met532Ile) single nucleotide variant Uncertain significance rs757909841 GRCh37 Chromosome 2, 49190364: 49190364
42 FSHR NM_000145.3(FSHR): c.1596G> A (p.Met532Ile) single nucleotide variant Uncertain significance rs757909841 GRCh38 Chromosome 2, 48963225: 48963225
43 FSHR NM_000145.3(FSHR): c.1030G> C (p.Val344Leu) single nucleotide variant Uncertain significance rs772756688 GRCh38 Chromosome 2, 48963791: 48963791
44 FSHR NM_000145.3(FSHR): c.1030G> C (p.Val344Leu) single nucleotide variant Uncertain significance rs772756688 GRCh37 Chromosome 2, 49190930: 49190930
45 FSHR NM_000145.3(FSHR): c.947A> G (p.Glu316Gly) single nucleotide variant Uncertain significance rs886056150 GRCh38 Chromosome 2, 48963874: 48963874
46 FSHR NM_000145.3(FSHR): c.947A> G (p.Glu316Gly) single nucleotide variant Uncertain significance rs886056150 GRCh37 Chromosome 2, 49191013: 49191013
47 FSHR NM_000145.3(FSHR): c.*246T> A single nucleotide variant Likely benign rs72825259 GRCh37 Chromosome 2, 49189626: 49189626
48 FSHR NM_000145.3(FSHR): c.*246T> A single nucleotide variant Likely benign rs72825259 GRCh38 Chromosome 2, 48962487: 48962487
49 FSHR NM_000145.3(FSHR): c.1330G> A (p.Ala444Thr) single nucleotide variant Uncertain significance rs202162496 GRCh38 Chromosome 2, 48963491: 48963491
50 FSHR NM_000145.3(FSHR): c.1330G> A (p.Ala444Thr) single nucleotide variant Uncertain significance rs202162496 GRCh37 Chromosome 2, 49190630: 49190630

Expression for Ovarian Hyperstimulation Syndrome

Search GEO for disease gene expression data for Ovarian Hyperstimulation Syndrome.

Pathways for Ovarian Hyperstimulation Syndrome

Pathways related to Ovarian Hyperstimulation Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

Pathways related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.02 CDH5 CGA FSHB GNRH1 KDR VEGFA
2
Show member pathways
12.24 CGA FSHB GNRH1 KDR VEGFA
3
Show member pathways
12.04 AMH FSHB FSHR
4
Show member pathways
11.98 CGA FSHB REN
5 11.85 CGA FSHB FSHR
6 11.81 CDH5 KDR VEGFA
7 11.78 ALB KDR VEGFA
8
Show member pathways
11.67 CDH5 KDR VEGFA
9
Show member pathways
11.51 CDH5 KDR VEGFA
10 11.45 CDH5 KDR REN
11 11.15 CGA CYP19A1 FSHB FSHR
12 11.11 KDR VEGFA
13 11.07 CYP19A1 FSHR
14 10.92 KDR VEGFA
15 10.89 FSHB FSHR
16 10.69 CGA CYP19A1 FSHB FSHR
17
Show member pathways
10.66 KDR VEGFA
18 10.04 CGA FSHB FSHR GNRH1

GO Terms for Ovarian Hyperstimulation Syndrome

Cellular components related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 ALB AMH CGA F5 FSHB GNRH1
2 platelet alpha granule lumen GO:0031093 9.43 ALB F5 VEGFA
3 extracellular region GO:0005576 9.28 ALB AMH CGA F5 FSHB GNRH1
4 follicle-stimulating hormone complex GO:0016914 9.16 CGA FSHB

Biological processes related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.9 ALB GNRH1 KDR VEGFA
2 positive regulation of cell proliferation GO:0008284 9.89 CGA FSHB KDR VEGFA
3 positive regulation of angiogenesis GO:0045766 9.73 CDH5 KDR VEGFA
4 positive regulation of cell migration GO:0030335 9.73 CGA FSHB KDR VEGFA
5 platelet degranulation GO:0002576 9.67 ALB F5 VEGFA
6 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.61 KDR VEGFA
7 positive regulation of focal adhesion assembly GO:0051894 9.58 KDR VEGFA
8 female gonad development GO:0008585 9.58 CYP19A1 FSHR
9 cell migration involved in sprouting angiogenesis GO:0002042 9.57 KDR VEGFA
10 peptide hormone processing GO:0016486 9.55 CGA FSHB
11 regulation of signaling receptor activity GO:0010469 9.55 AMH CGA FSHB GNRH1 VEGFA
12 female gamete generation GO:0007292 9.54 FSHB FSHR
13 uterus development GO:0060065 9.52 CYP19A1 FSHR
14 vascular endothelial growth factor signaling pathway GO:0038084 9.51 KDR VEGFA
15 hormone-mediated signaling pathway GO:0009755 9.5 FSHB FSHR REN
16 regulation of osteoclast differentiation GO:0045670 9.48 FSHB FSHR
17 positive regulation of positive chemotaxis GO:0050927 9.46 KDR VEGFA
18 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.4 KDR VEGFA
19 Sertoli cell proliferation GO:0060011 9.37 FSHB FSHR
20 follicle-stimulating hormone signaling pathway GO:0042699 9.26 FSHB FSHR
21 positive regulation of steroid biosynthetic process GO:0010893 8.96 CGA FSHB
22 gonad development GO:0008406 8.8 AMH CGA FSHR

Molecular functions related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 9.16 ALB CYP19A1
2 follicle-stimulating hormone activity GO:0016913 8.96 CGA FSHB
3 hormone activity GO:0005179 8.92 AMH CGA FSHB GNRH1

Sources for Ovarian Hyperstimulation Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....